- Previous Close
485.30 - Open
486.00 - Bid --
- Ask 491.25 x --
- Day's Range
479.35 - 493.00 - 52 Week Range
358.00 - 518.00 - Volume
1,773,493 - Avg. Volume
2,756,341 - Market Cap (intraday)
264.862B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
202.16 - EPS (TTM)
2.43 - Earnings Date Jan 22, 2025 - Jan 27, 2025
- Forward Dividend & Yield 0.80 (0.16%)
- Ex-Dividend Date Nov 6, 2024
- 1y Target Est
559.67
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
www.lauruslabs.com6,007
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: LAURUSLABS.NS
View More
Performance Overview: LAURUSLABS.NS
Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LAURUSLABS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LAURUSLABS.NS
View MoreValuation Measures
Market Cap
261.57B
Enterprise Value
288.94B
Trailing P/E
199.71
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.22
Price/Book (mrq)
6.33
Enterprise Value/Revenue
5.76
Enterprise Value/EBITDA
36.60
Financial Highlights
Profitability and Income Statement
Profit Margin
2.59%
Return on Assets (ttm)
2.68%
Return on Equity (ttm)
3.20%
Revenue (ttm)
50.53B
Net Income Avi to Common (ttm)
1.31B
Diluted EPS (ttm)
2.43
Balance Sheet and Cash Flow
Total Cash (mrq)
449.2M
Total Debt/Equity (mrq)
67.30%
Levered Free Cash Flow (ttm)
-6.32B
Research Analysis: LAURUSLABS.NS
View MoreCompany Insights: LAURUSLABS.NS
LAURUSLABS.NS does not have Company Insights